HIV
Conditions
Keywords
vaccine
Brief summary
The object of the study is to assess the safety profile of candidate vaccines ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVcnsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers. In addition, the study will assess the immune responses generated of the candidate vaccines ChAdOx1.tHIVconsv1, MV.tHIVconsv3 and MVA.tHIVconsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers. 3 healthy, HIV-1 negative adult volunteers will receive one vaccination of low dose ChAdOx1.tHIVconsv1. A further 10 healthy, HIV-1 negative adult volunteers will receive a higher dose of ChAdOx1.tHIVconsv1, followed by one vaccination each of MVA.tHIVconsv3 and MVA.tHIVconsv4 4 weeks later.
Interventions
BIOLOGICALChAdOx1.tHIVconsv1 (C1)
ChAdOx1.tHIVconsv1 5 x 10\^9 vp
BIOLOGICALMVA.tHIVconsv3 (M3)
MVA.tHIVconsv3 1 x 10\^8 pfu
BIOLOGICALMVA.tHIVconsv4 (M4)
MVA.tHIVconsv4 09. x 10\^8 pfu
Sponsors
University of Oxford
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
The first three participants will receive a low dose of ChAdOx1.tHIVconsv1 only. A further ten participants will receive a higher dose of ChAdOx1.tHIVconsv1 and a subsequent vaccination of MVA.tHIVconsv3 and MVA.tHIVconsv4
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult aged 18-65 years * Able and willing (in the Investigator's opinion) to comply with all study requirements * Willing to allow the investigators to discuss the volunteer's medical history with their GP * Women of child-bearing potential agree to practice continuous effective contraception during the study and test negative for pregnancy on the day(s) of screening and vaccination * For sexually active men, willingness to use barrier methods for the purposes of contraception from screening until 4 months after the last vaccination * Agreement to refrain from blood donation during the course of the study * In the opinion of the Investigators, the volunteer has understood the information provided Written informed consent must be given before any study-related procedures are performed * Willing to undergo HCV, HBV, syphilis and HIV testing and counselling and receive test results
Exclusion criteria
* Confirmed HIV-1 or HIV-2 infection * Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period * Prior receipt of a recombinant simian adenoviral vaccine prior to enrolment * Planned receipt of another adenoviral vectored vaccine within 90 days after the vaccination with the ChAdOx1.tHIVconsv1 IMP * Receipt of any investigational HIV-1/2 vaccine * Receipt of live attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with the IMP * Receipt of other vaccine, including influenza vaccine, within the previous 14 days or planned receipt within 14 days after vaccination with the IMP * Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate * Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV-1/2 infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed) * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine * Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema. * Any history of anaphylaxis in relation to vaccination * Pregnancy, lactation or willingness/intention to become pregnant during the study * History of cancer (except basal cell carcinoma of the skin) * History of serious psychiatric condition likely to affect participation in the study * Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture * Any other serious chronic illness requiring hospital specialist supervision * Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week * Suspected or known injecting drug abuse in the 5 years preceding enrolment * Reported high-risk behaviour for HIV-1/2 infection. High-risk behaviour for HIV-1/2 infection is defined as follows. Within the previous 12 months the volunteer has: * Had unprotected vaginal or anal sex with a person infected with HIV and not taking effective treatment, injecting drug users or casual partners (i.e., no continuing, established relationship) * Engaged in sex work for money or drugs * Used injection drugs * Acquired one of the following sexually transmitted infection: chlamydia, gonorrhea and syphilis. * Seropositive for hepatitis B surface antigen (HBsAg) * Seropositive for hepatitis C virus (antibodies to HCV) * Untreated Syphilis: Treponemal IgG/IgM and positive RPR/TPPA AND no documentation of adequate treatment * Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessement of Safety | 140 days | • Proportion of volunteers with vaccine related serious adverse events (SAEs) collected up to day 140 after enrollment. |
| Assement of Safety | up to 28 days after each vaccination | Proportion of volunteers with Grade 3 or 4 unsolicited adverse events (AEs) through 28 days post final vaccination |
| Assessment of Safety | up to day 7 | Proportion of volunteers with local and systemic reactogenicity events from Day 0 to Day 6 post vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the Immunogenicity of the ChAdOx1.tHIVconsv1 and MVA.tHIVconsv3 & 4 Vaccines Administered Sequentially. | Up to 5 months | The proportion of participants that develop T-cell responses to tHIVconsvx measured by IFN-gamma ELISpot assay |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| ChAdOx1.tHIVconsv1 Low Dose 3 participants received one dose of ChAdOx1.tHIVconsv1 at 5 x 10\^9 vp
ChAdOx1.tHIVconsv1 (C1): ChAdOx1.tHIVconsv1 5 x 10\^9 vp | 3 |
| ChADOx1.tHIVconsv1 Higher Dose 10 participants received one dose of ChAdOx1.tHIVconsv1 at 5 x 10\^10 vp and one dose each of MVA.tHIVconsv3 at 1 x 10\^8 pfu and MVA.tHIVconsv4 at 0.9 x 10\^8 pfu.
ChAdOx1.tHIVconsv1 (C1): ChAdOx1.tHIVconsv1 5 x 10\^10 vp
MVA.tHIVconsv3 (M3): MVA.tHIVconsv3 1 x 10\^8 pfu
MVA.tHIVconsv4 (M4): MVA.tHIVconsv4 09. x 10\^8 pfu | 10 |
| Total | 13 |
Baseline characteristics
| Characteristic | ChAdOx1.tHIVconsv1 Low Dose | ChADOx1.tHIVconsv1 Higher Dose | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants | 10 Participants | 13 Participants |
| Age, Continuous | 38 years | 30 years | 30 years |
| Race/Ethnicity, Customized White, White British | 3 Participants | 10 Participants | 13 Participants |
| Region of Enrollment United Kingdom | 3 participants | 10 participants | 13 participants |
| Sex: Female, Male Female | 1 Participants | 4 Participants | 5 Participants |
| Sex: Female, Male Male | 2 Participants | 6 Participants | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 10 |
| other Total, other adverse events | 3 / 3 | 10 / 10 |
| serious Total, serious adverse events | 0 / 3 | 0 / 10 |
Outcome results
Primary
Assement of Safety
Proportion of volunteers with Grade 3 or 4 unsolicited adverse events (AEs) through 28 days post final vaccination
Time frame: up to 28 days after each vaccination
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| ChAdOx1.tHIVconsv1 Low Dose | Assement of Safety | 0 Participants |
| ChADOx1.tHIVconsv1 Higher Dose | Assement of Safety | 6 Participants |
Primary
Assessement of Safety
• Proportion of volunteers with vaccine related serious adverse events (SAEs) collected up to day 140 after enrollment.
Time frame: 140 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| ChAdOx1.tHIVconsv1 Low Dose | Assessement of Safety | 0 Participants |
| ChADOx1.tHIVconsv1 Higher Dose | Assessement of Safety | 0 Participants |
Primary
Assessment of Safety
Proportion of volunteers with local and systemic reactogenicity events from Day 0 to Day 6 post vaccination
Time frame: up to day 7
Population: All volunteers were included in the analysis, and all experienced at least one solicited AE after vaccination
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| ChAdOx1.tHIVconsv1 Low Dose | Assessment of Safety | 3 Participants |
| ChADOx1.tHIVconsv1 Higher Dose | Assessment of Safety | 10 Participants |
Secondary
Assessment of the Immunogenicity of the ChAdOx1.tHIVconsv1 and MVA.tHIVconsv3 & 4 Vaccines Administered Sequentially.
The proportion of participants that develop T-cell responses to tHIVconsvx measured by IFN-gamma ELISpot assay
Time frame: Up to 5 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| ChAdOx1.tHIVconsv1 Low Dose | Assessment of the Immunogenicity of the ChAdOx1.tHIVconsv1 and MVA.tHIVconsv3 & 4 Vaccines Administered Sequentially. | 3 Participants |
| ChADOx1.tHIVconsv1 Higher Dose | Assessment of the Immunogenicity of the ChAdOx1.tHIVconsv1 and MVA.tHIVconsv3 & 4 Vaccines Administered Sequentially. | 10 Participants |